Pacira BioSciences Balance Sheet Health

Financial Health criteria checks 5/6

Pacira BioSciences hat ein Gesamteigenkapital von $831.6M und eine Gesamtverschuldung von $524.6M, wodurch sich der Verschuldungsgrad auf 63.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $1.5B bzw. $702.9M. Pacira BioSciences Das EBIT des Unternehmens beträgt $78.1M, so dass der Zinsdeckungsgrad 4.6 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $235.2M.

Key information

60.0%

Debt to equity ratio

US$522.44m

Debt

Interest coverage ratio	9.9x
Cash	US$278.58m
Equity	US$870.13m
Total liabilities	US$704.26m
Total assets	US$1.57b

Recent financial health updates

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04

Recent updates

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

Feb 05

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Jan 05

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Nov 03

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Jul 28

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04

Pacira BioSciences: Higher Prices On The Horizon

Dec 20

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Nov 29

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Oct 15

Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months

Sep 17

Pacira Biosciences' EXPAREL average daily sales more than doubles in May

Jun 08

Pacira Bio's Exparel fails to reach primary endpoint in late-stage STRIDE study

May 26

Financial Position Analysis

Kurzfristige Verbindlichkeiten: PCRXDie kurzfristigen Aktiva des Unternehmens ($447.3M) übersteigen seine kurzfristigen Passiva ($93.7M).

Langfristige Verbindlichkeiten: PCRXDie kurzfristigen Vermögenswerte des Unternehmens ($447.3M) decken seine langfristigen Verbindlichkeiten ($609.3M) nicht.

Debt to Equity History and Analysis

Verschuldungsgrad: PCRXDie Nettoverschuldung im Verhältnis zum Eigenkapital (34.8%) wird als zufriedenstellend angesehen.

Schulden abbauen: PCRX Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 95.3% auf 63.1% zurückgegangen.

Schuldendeckung: PCRXDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (28.4%).

Zinsdeckung: Die Zinszahlungen für die Schulden von PCRX sind durch das EBIT gut gedeckt (4.6x coverage).

Balance Sheet

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Pacira BioSciences Balance Sheet Health

Financial Health criteria checks 5/6

Key information

Recent financial health updates

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Recent updates

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Pacira BioSciences records 17.7% sequential growth in August revenue

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences provides update on July product sales

Pacira BioSciences Q2 2022 Earnings Preview

Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Pacira BioSciences sees Q2 revenue below consensus

Chief Clinical Officer recently sold US$53k worth of stock

Chief Technical Officer exercised options to buy US$322k worth of stock.

Investor sentiment deteriorated over the past week

Chairman & CEO recently sold US$734k worth of stock

Chief Clinical Officer exercised options to buy US$129k worth of stock.

Independent Director recently sold US$59k worth of stock

Consensus EPS estimates fall by 28%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman & CEO exercised options to buy US$1.5m worth of stock.

President of Rest of World exercised options and sold US$861k worth of stock

Insufficient new directors

Pacira BioSciences, Inc., Annual General Meeting, Jun 07, 2022

President of Rest of World exercised options and sold US$861k worth of stock

Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well